A research team led by Professor Ja Hyoung Ryu from UNIST reports on a promising new approach to treat age-related diseases by selectively removing aging cells, without harming normal healthy cells in the latest issue of the Journal of the American Chemical Society.
Senolytics, which eliminate senescent cells from tissues, represent an emerging therapeutic strategy for various age-related diseases. Most senolytics target antiapoptotic proteins, which are overexpressed in senescent cells, limiting specificity and inducing severe side effects. To overcome these limitations, the UNIST team engineered organic molecules designed to target receptors overly expressed on aging cell membranes. These molecules exploited the higher levels of reactive oxygen species (ROS) present in aging cells, promoting the formation of disulfide bonds and creating oligomers that could bind together.
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
Through the self-assembly of these oligomers, the scientists successfully generated artificial proteins with a stable α-helix secondary structure. These protein-like nanoassemblies exhibited a strong affinity for the mitochondrial membranes of aging cells, leading to membrane disruption and subsequent cell self-destruction.
Professor Ryu commented, "Our experiments have successfully demonstrated the selective removal of aging cells by targeting the mitochondria and inducing dysfunction. This approach represents a new paradigm for treating age-related diseases."